Physician profile
Dale Budd
NPI 1184713935
$757.40
in general payments reported to CMS, 2019-2025
13 companies · $194 in 2025
The $194 reported for 2025 was more than what 88% of Chiropractor providers received nationally (typical 2025 total: $40.91).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.29 · 2020: $57.90 · 2021: $142 · 2022: $104 · 2023: $88.36 · 2024: $131 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $413.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $142.62 | 2025 | Trintellix |
| International Rehabilitative Sciences, INC | $121.73 | 2021-2024 | Rs 4i Plus Sequential Stimulator |
| Axsome Therapeutics, INC. | $96.61 | 2022-2025 | Auvelity |
| Novo Nordisk INC | $89.40 | 2021-2024 | Ozempic, Rybelsus |
| Redhill Biopharma INC. | $66.86 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $59.56 | 2023-2024 | Quviviq |
| Smith+Nephew, INC. | $50.52 | 2023 | Collagenase Santyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.29 | 2019 | |
| Zyla Life Sciences, INC. | $25.50 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $21.23 | 2020 | |
| Jazz Pharmaceuticals INC. | $17.56 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $14.35 | 2025 | |
| Genentech USA, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Budd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.